Pre-Conference Workshops

Morning Workshops

Workshop A:  6am-9am PST | 9am-12pm EST

A Deep Dive into Potency Assays

Navigating the challenges of developing clinically relevant potency assays for gene therapy products

Workshop Leader:

Marina Feschenko, Director - Analytical Development, Biogen

Hui-wen Liu, Scientist I , Biogen

Workshop B: 6am-9am PST | 9am-12pm EST

The Switch to Digital PCR

Discussing the challenges of switching from qPCR to digital PCR, whilst exploring the advantages and limitations of each technology

Workshop Leader:

Clare Blue, Director, Analytical Development, Biogen

David Dobnik, Scientific Associate, Head of Laboratory for Therapeutic Viruses, National Institute of Biology

Yu Wang, Senior Scientist, Analytical Development, Biogen


Workshop C: 6am-9am PST | 9am-12pm EST

The Effort for QC-Friendly Empty-Full & Partial Characterisation

Exploring the analytical technologies used for empty-full characterisation and how these can be incorporated into a suitable QC environment

Workshop Leader:

John Little, Director, Quality Control, Freeline Therapeutics

Afternoon Workshops

Workshop D:  10am-1pm PST | 1pm-4pm EST

Ex Vivo Gene Therapy Product Analytics

Discussing the specific analytical challenges for ex vivo
gene therapy products, from potency to characterization.

Workshop Leader:

Scott Burger, Principal, Advanced Cell & Gene Therapy, LLC

Workshop E: 10am-1pm PST | 1pm-4pm EST

High Throughput: Next Generation Sequencing Technology

Discovering the potential of characterization of AAV stocks by high-throughput sequencing: residual DNA, genome identity and integrity, sequencing biases

Workshop Leader:

Magalie Penaud-Budloo, Postdoctoral Research Scientist, Translational Gene Therapy for Genetic Diseases, INSERM

Workshop F: 10am-1pm PST | 1pm-4pm EST

Characterizing Aggregates

Developing orthogonal methods for rAAV vector aggregate characterization and exploring the advantages and disadvantages of DLS, SEC-HPLC, nsTEM and other methods

Workshop Leaders:

Franz Schnetzinger, Director, Quality Control & CMC Analytical Development, Gyroscope Therapeutics

Andrea Hamilton, QC Senior Scientist, Gyroscope Therapeutics